InflaRx (IFRX) Current Assets (2016 - 2026)
InflaRx (IFRX) posted Current Assets of $55.5 million for Q1 2026, down 11.12% sequentially from $62.4 million in Q4 2025, and down 38.38% YoY from $90.1 million in Q1 2025.
InflaRx (IFRX) Current Assets (2016 - 2026) Analysis & Trends
InflaRx has reported Current Assets for 11 years, with the latest figure at $55.5 million in Q1 2026.
- Quarterly Current Assets fell 38.38% year-over-year to $55.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.5 million (down 38.38% YoY) and the FY2025 annual result came in at $60.6 million, down 21.87% from the prior year.
- Current Assets fell to $55.5 million in Q1 2026 per IFRX's latest filing, from $62.4 million in the prior quarter.
- Over five years, Current Assets peaked at $138.8 million in Q3 2023 and troughed at $55.5 million in Q1 2026.
- A 5-year average of $95.9 million and a median of $98.3 million in 2024 frame the typical range for Current Assets.
- The widest YoY moves for Current Assets: up 36.39% in 2024, down 41.76% in 2024.
- Over 5 years, Current Assets stood at $99.4 million in 2022, then increased by 18.51% to $117.8 million in 2023, then plunged by 34.99% to $76.6 million in 2024, then slipped by 18.46% to $62.4 million in 2025, then slipped by 11.12% to $55.5 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $55.5 million, $62.4 million, and $74.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 192.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.49 Mn |
| Dec 31, 2025 | 62.43 Mn |
| Sep 30, 2025 | 74.20 Mn |
| Jun 30, 2025 | 74.90 Mn |
| Mar 31, 2025 | 90.05 Mn |
| Dec 31, 2024 | 76.57 Mn |
| Sep 30, 2024 | 80.85 Mn |
| Jun 30, 2024 | 98.32 Mn |
| Mar 31, 2024 | 111.86 Mn |
| Dec 31, 2023 | 117.78 Mn |
| Sep 30, 2023 | 138.83 Mn |
| Jun 30, 2023 | 122.20 Mn |
| Mar 31, 2023 | 82.01 Mn |
| Dec 31, 2022 | 99.38 Mn |
| Sep 30, 2022 | 109.63 Mn |
| Jun 30, 2022 | 119.65 Mn |
| Mar 31, 2022 | 116.38 Mn |
| Dec 31, 2021 | 109.45 Mn |
| Sep 30, 2021 | 118.23 Mn |
| Jun 30, 2021 | 159.19 Mn |